Tubulin polymerization-IN-43 is an inhibitor of tubulin polymerisation.Tubulin polymerization-IN-43 has multiple effects, disrupting the cellular microtubule network by targeting the colchicine locus and promoting cell cycle arrest and apoptosis in leukaemia cells. Tubulin polymerisation-IN-43 has multiple effects, promoting leukaemia cell cycle arrest in G2/M phase and apoptosis by targeting Colchicine sites to disrupt the cellular microtubule network.

Tubulin inhibitor 8 is an inhibitor of tubulin and various cancer cell lines and inhibits tubulin polymerisation and K562 cell growth with an IC50 of 0.73 μM and 14 nM respectively.

Tubulin inhibitor 32 is an orally active novel microtubule inhibitor with antiproliferative and antitumor activity, inhibits microtubule polymerization, induces apoptosis and cell cycle arrest in G2/M phase.

Tubulin inhibitor 24 is a potent inhibitor that can inhibit tubulin polymerization.

Tubulin inhibitor 35 (Tubulin IN 35) is a potent dual inhibitor of topoisomerase I and microtubule protein polymerization with antitumor activity, inhibits migration and invasion of MGC-803 and RKO cell lines, interrupts the cell cycle and induces apoptosis.

Tubulin Polymerization-IN-51 (compound 7u) serves as a tubulin polymerization inhibitor, exhibiting an IC50 range of 2.55 - 17.89μM against SK-Mel-28 cells, and is applicable in cancer research [1].

Tubulin polymerization-IN-53 (compound 4b) serves as an inhibitor of β-tubulin polymerization and is capable of arresting the cell cycle at the G2/M stage. It demonstrates antiproliferative efficacy against the MDA-MB-231 cell line, with an IC50 value of 3.24 μM [1].

Tubulin/JAK2-IN-1 (compound 7g) serves as a potent dual inhibitor targeting both Janus kinase 2 (JAK2) and microtubules, demonstrating significant antiproliferative effects against cancer cells [1].

Tubulin polymerization-IN-55 is a potent Tubulin Polymerization inhibitor with potential anti-angiogenic and anti-tumour activity, showing anti-proliferative effects against A549, K562, HepG2, MDA-MB-231 and HFL-1.

Tubulin Polymerization-IN-56 (compound 8l), an indazole derivative, potently inhibits tubulin polymerization by targeting the colchicine site, which induces cell cycle arrest and apoptosis. Additionally, this compound diminishes cell migration and significantly inhibits tumor growth in vivo [1].

Tubulin inhibitor 6 (iHAP1) is an inhibitor of tubulin and a potent inhibitor of multiple cancer cell lines.

Tubulin polymerization-IN-47 is a tubulin polymerization inhibitor and mitotic inhibitor with antitumor activity and inhibitory effects on neuroblastoma cancer cell proliferation, with IC50s of 7 and 12 nM for Chp-134 and Kelly cell lines, respectively. Tubulin polymerization-IN-47 is a candidate compound for the treatment of hepatocellular carcinoma, colon cancer, lung cancer and breast cancer.

Tubulin inhibitor 1 is an inhibitor of tubulin, inhibits tubulin polymerization, with potent anti-tumor activity, induces cellular apoptosis causes and cellular mitotic arrest in the G2/M phase.

Tubulin polymerization-IN-29 is a potent inhibitor of microtubule protein polymerization and shows potent anti-proliferative effects.Tubulin polymerization-IN-29 induces cell cycle arrest in HeLa cells at G2/M phase.

Tubulin polymerization-IN-46 (compound 9q) is a microtubule/tubulin inhibitor that impedes tubulin polymerization, induces apoptosis, and arrests MCF-7 breast cancer cells in the G2/M phase, exhibiting potent anti-proliferative activity with an IC50 of 10 nM [1].

Tubulin Inhibitor 38 (Compound 14), a tetrazole-based agent, demonstrates significant antiproliferative effects by inducing mitotic arrest and blocking the cell cycle at the G2/M phase, ultimately triggering apoptosis. Administered at 100 nM for 24 hours, it shows considerable cytotoxicity and selectivity within HeLa, MCF7, and U87 MG cell lines [1].

Tubulin polymerization-IN-45, a tubulin-targeting agent, acts as a tubulin polymerization inhibitor by binding to the tubulin's colchicine site. It induces apoptotic cell death in hepatocellular cancer (HCC) cells [1].

Tubulin Inhibitor 37 (Compound 12) effectively impedes tubulin aggregation (IC50 = 1.3 µM) and demonstrates antiproliferative activity against human tumor cell lines, showing promise for cancer research [1].

Tubulin Inhibitor 36 (Compound 10) serves as a potent novel inhibitor of tubulin polymerization, which consequently induces apoptosis in glioblastoma cells, reflected by an IC50 value of 1.5±0.1 μM. Exhibiting significant anti-mitotic activity, this compound demonstrates anti-tumor potential, particularly useful in glioblastoma multiforme (GBM) research [1].

Tubulin Inhibitor 33 is a dose-dependent inhibitor of tubulin polymerization, exhibiting an IC50 value of 9.05 μM. This compound demonstrates antitumor activity and induces apoptosis, making it useful for antitumor research [1].

Tubulin inhibitor 14 is a potent inhibitor of NQO2 (quinone oxidoreductase 2) with an IC50 of 1.0 μM which also inhibits tubulin polymerization and the formation of endothelial cell capillary-like tubes. Tubulin inhibitor 14 is a microtubule destabilizer with potential tumor-selective as well as anti-angiogenic and vascular-destructive properties [1].

Tubulin polymerization-IN-35 is [1,2] an inhibitor of oxazolylisoindole microtubulin polymerization that acts highly selectively on the marginal zone lymphoma VL51 cell line.

Tubulin polymerization-IN-14 (Compound 20a) is a tubulin polymerization inhibitor (IC 50 = 3.15 μM) that exhibits potent anti-vascular and anticancer activities including cancer cell apoptosis [1].

IDO/Tubulin-IN-2 (HT2) is a powerful inhibitor of both TDO and tubulin. This compound demonstrates significant efficacy against various cancer cell lines, including U87, HepG2, A549, HCT-116, and LO2, with respective IC50 values of 0.43, 0.036, 0.041, 0.095, and 1.04 μM. Additionally, IDO/Tubulin-IN-2 markedly enhances antitumor activity [1].

Tubulin polymerization-IN-39, a tubulin polymerization inhibitor with an IC50 of 4.9 μM, targets the colchicine-binding site to hinder tubulin polymerization. This compound effectively suppresses cancer cell proliferation.

Tubulin polymerization-IN-26 (compound 12h) is a chemical compound that inhibits the polymerization of microtubulin. It achieves this by binding to the colchicine binding site of microtubulin, with an IC50 value of 4.64 μM. Additionally, Tubulin polymerization-IN-26 has the ability to induce apoptosis and inhibit cell metastasis or migration. Due to these properties, it holds potential as a valuable compound for researching lung cancer [1].

Tubulin polymerization-IN-32 is a tubulin polymerization inhibitor that inhibits the proliferation of cancer cells and can be used to study cancers such as lymphoma.

Tubulin polymerization-IN-9 is a potent inhibitor of tubulin (IC50: 1.82 μM). Tubulin polymerization-IN-9 arrests the cell cycle of K562 cells in G2/M phase and induces apoptosis and mitochondrial depolarization. Tubulin polymerization-IN-9 exhibits potent anti-vascular and anti-tumour effects.

Tubulin Inhibitor 11 is a potent, orally active agent that inhibits tubulin by targeting the Colchicine binding site. It impedes tubulin polymerization, leading to mitotic blockade and apoptosis.

Tubulin polymerization-IN-42 (compound 10j), an indole-substituted furanone, inhibits tubulin polymerization and exhibits anti-cancer properties [1].

Tubulin/HDAC-IN-2 (Compound II-19k) is a dual inhibitor targeting Tubulin and HDAC, exhibiting IC50 values of 0.403 μM for HDAC1, 0.591 μM for HDAC2, 3.552 μM for HDAC3, and 0.459 μM for HDAC6. The compound induces G2 phase cell cycle arrest and promotes apoptosis. It effectively hampers the proliferation of both hematoma and solid tumor cells, diminishes tumor metastasis, and demonstrates tumor growth inhibition in a liver tumor allograft mouse model [1].

Tubulin polymerization-IN-52 (compound SC23) effectively inhibits tubulin polymerization, exhibiting an IC50 value of 2.9 μM [1].

Tubulin polymerization-IN-6 (compound 5f) is a potent inhibitor of tubulin polymerization, with an IC50 of 1.09 μM. It not only inhibits cell migration and tube formation but also has anti-angiogenic properties. Additionally, Tubulin polymerization-IN-6 has been found to effectively hinder tumor growth in HT29 xenograft Balb/c nude mice [1].

Tubulin polymerization-IN-31 (Compound 4c) has antitumor activity and induces apoptosis of cancer cell. Tubulin polymerization-IN-31 is an inhibitor of tubulin polymerization with an IC 50 value of 3.64 μM [1].

Tubulin polymerization-IN-8 (compound IIc) is a potent inhibitor of tubulin polymerization that has been demonstrated to concentration-dependently induce cell cycle arrest at the G2/M phase in HCT116 tumor cells. It also significantly inhibits tubulin polymerization with an IC50 value of 12.7 μM, showing potential for cancer research [1].

Tubulin polymerization-IN-33 is an [1,2] inhibitor of oxazoloisoindole microtubulin polymerization and is a good anti-proliferative agent for NCI series cancer cells.

Tubulin inhibitor 23 is a potent Tubulin inhibitor (IC50: 4.8 μM). Tubulin inhibitor 23 exhibited antiangiogenic effects in a dose-dependent manner and could induce apoptosis. Tubulin inhibitor 23 has potential for leukemia research.

Tubulin inhibitor 20 (compound 1) shows the potential for the cancer research that is a potent tubulin inhibitor [1].

Tubulin Inhibitor 27 (DYT-1), a compound that inhibits tubulin polymerization with an IC50 of 25.6 μM, exhibits anti-angiogenesis and antitumor activities [1].

Tubulin inhibitor 19 (compound 9b) is a potent indole chalcone compound that exhibits strong inhibitory activity against tubulin. Its potential in cancer research makes it valuable for studying cancer diseases [1].

Tubulin polymerization-IN-21 is an inhibitor of microtubulin polymerization that disrupts cell integrity and affects glucose metabolism, and has anticancer effects.

Tubulin polymerization-IN-10 is a highly potent inhibitor of tubulin polymerization, exhibiting an IC50 value of 4.25±0.75 μM. It possesses significant anti-tumor properties [1].

Tubulin inhibitor 29 (compound 3c) is a potent tubulin inhibitor that inhibits tubulin assembly and bounds in the colchicine site (IC 50 = 1.2 μM). Tubulin inhibitor 29 exhibits antiproliferative effects with an IC 50 value of 7.5 μM for MCF-7 cells. [1].

Tubulin polymerization-IN-25 is a selective, dual tubulin polymerization (IC50: 1.11 μM) and farnesyl transferase (FTase) (IC50: 0.39 μM) inhibitor. polymerization-IN-25 exhibits cytotoxicity against cancer cells and blocks cell proliferation.

Tubulin Polymerization-IN-2 is a powerful anticancer agent that targets β-tubulin, exhibiting an IC 50 of 0.92 μM. It demonstrates promising efficacy against a range of cancer cell lines including leukemia, non-small cell lung, renal, prostate, and breast cancers [1].

Tubulin inhibitor 17 (Compound 3b) is an inhibitor of tubulin polymerization (IC50 = 12.38 µM). Tubulin inhibitor 17 exhibits anticancer activities as well as induces cell apoptosis[1].

Tubulin polymerization-IN-4 is an effective inhibitor of tubulin polymerization (IC50=4.6 μM）。 Tubulin polymerization-IN-4 can destroy tubulin polymerization, block cell cycle at G2/M phase, induce apoptosis, and inhibit cell cloning and migration. Tubulin polymerization-IN-4 can also damage the vascular system.

Tubulin Inhibitor 34 (compound b5), a potent anticancer agent, inhibits tubulin polymerization and induces G2/M arrest and apoptosis. The compound demonstrates significant antivascular and antitumor activity [1].

Tubulinpolymer-in-44 (compound 7w) effectively inhibits Tubulin with an IC50 value of 0.21 μM and induces apoptosis by arresting the G2/M phase, making it useful for cancer research.

Tubulin inhibitor 16 is a potent tubulin inhibitor with antiproliferative activity. Tubulin inhibitor 16 exhibits cytotoxicity in HepG2 cells [1].